15 Best Biotech Stocks to Buy According to Billionaires

Page 7 of 13

7. Insmed Incorporated (NASDAQ:INSM)

Number of Billionaires: 14 

Dollar Value of Billionaire Holdings: $678,946,853 

The seventh stock on our list of the best biotech stocks to buy according to billionaires is Insmed Incorporated (NASDAQ:INSM). It is a global biopharmaceutical company focused on developing treatments for rare diseases, particularly those affecting the lungs. Its leading therapy, ARIKAYCE (amikacin liposome inhalation suspension), is used to treat Mycobacterium avium complex (MAC) lung disease in patients with limited treatment options. The company is also developing other therapies, including Brensocatib, a drug for bronchiectasis, and TPIP, a treatment for pulmonary hypertension related to lung diseases.

In its Q4 2024 financial report, Insmed Incorporated (NASDAQ:INSM) announced record revenue growth of 19%, reaching $363.7 million for the year. The company saw strong performance across different regions: US revenue grew by 14%, Japan’s by 33%, and Europe and the rest of the world by 39%. Its ARIKAYCE continues to drive growth, with revenue projections for 2025 expected between $405 million and $425 million.

Insmed Incorporated (NASDAQ:INSM) finished 2024 with a solid cash position of over $1.4 billion, though it reported a Q4 cash burn of $191 million due to investments in Brensocatib’s launch. Despite these costs, the company’s research and development (R&D) expenses were significant at $599 million, and selling, general, and administrative (SG&A) expenses were $462 million. Encouraging Phase III results for Brensocatib also supports the drug’s potential for FDA approval and future commercial success.

Page 7 of 13